Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

714 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.
Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH, Dunbar M, Zhu M, Peale F, Ross JA, Gressick L, Desai M, Kim SY, Verdugo M, Humerickhouse RA, Gordon GB, Gerecitano JF. Davids MS, et al. Among authors: anderson ma. J Clin Oncol. 2017 Mar 10;35(8):826-833. doi: 10.1200/JCO.2016.70.4320. Epub 2017 Jan 17. J Clin Oncol. 2017. PMID: 28095146 Free PMC article.
Targeting BCL2 for the treatment of lymphoid malignancies.
Anderson MA, Huang D, Roberts A. Anderson MA, et al. Semin Hematol. 2014 Jul;51(3):219-27. doi: 10.1053/j.seminhematol.2014.05.008. Epub 2014 May 15. Semin Hematol. 2014. PMID: 25048785 Free article. Review.
BCL2 inhibition in double hit lymphoma.
Anderson MA, Huang DC, Roberts AW. Anderson MA, et al. Leuk Lymphoma. 2015 Jul;56(7):1928-9. doi: 10.3109/10428194.2014.987769. Epub 2015 Jan 21. Leuk Lymphoma. 2015. PMID: 25407655 No abstract available.
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L, Wong S, Dunbar M, Zhu M, Desai MB, Cerri E, Heitner Enschede S, Humerickhouse RA, Wierda WG, Seymour JF. Roberts AW, et al. Among authors: anderson ma. N Engl J Med. 2016 Jan 28;374(4):311-22. doi: 10.1056/NEJMoa1513257. Epub 2015 Dec 6. N Engl J Med. 2016. PMID: 26639348 Free PMC article. Clinical Trial.
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.
Anderson MA, Deng J, Seymour JF, Tam C, Kim SY, Fein J, Yu L, Brown JR, Westerman D, Si EG, Majewski IJ, Segal D, Heitner Enschede SL, Huang DC, Davids MS, Letai A, Roberts AW. Anderson MA, et al. Blood. 2016 Jun 23;127(25):3215-24. doi: 10.1182/blood-2016-01-688796. Epub 2016 Apr 11. Blood. 2016. PMID: 27069256 Free PMC article.
Transformed Lymphoma.
Anderson MA, Blombery P, Seymour JF. Anderson MA, et al. Hematol Oncol Clin North Am. 2016 Dec;30(6):1317-1332. doi: 10.1016/j.hoc.2016.07.012. Hematol Oncol Clin North Am. 2016. PMID: 27888883 Review.
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, Anderson MA, Beaven AW, Rosen ST, Tam CS, Prine B, Agarwal SK, Munasinghe W, Zhu M, Lash LL, Desai M, Cerri E, Verdugo M, Kim SY, Humerickhouse RA, Gordon GB, Kipps TJ, Roberts AW. Seymour JF, et al. Among authors: ma s, anderson ma. Lancet Oncol. 2017 Feb;18(2):230-240. doi: 10.1016/S1470-2045(17)30012-8. Epub 2017 Jan 13. Lancet Oncol. 2017. PMID: 28089635 Free PMC article. Clinical Trial.
714 results